A one-time inhaled vaccine that’s under development provides long-term protection for non-human primates against the deadly Ebola virus.
Published in Molecular Pharmaceutics, the findings of the pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.
[related]
A breathable vaccine could overcome the logistical obstacles of storing, transporting, and administering injectable vaccines in parts of Africa most afflicted by the virus.
The Ebola virus is an often fatal illness that is spread among the human population via direct contact with blood or bodily fluids from an infected individual.
The current Ebola outbreak in Western Africa is the largest and most complex epidemic since the virus was first discovered in 1976, according to the World Health Organization.
With a fatality rate currently as high as 70 percent, officials are declaring the outbreak a public health emergency of international concern.
100% survival
Researchers worked more than seven years to develop a respiratory formulation that improved survival of immunized non-human primates from 67 percent to 100 percent after challenge with 1,000 plaque forming units of Ebola Zaire 150 days after immunization.
The improvement is statistically significant because only 50 percent of the primates given the vaccine by the standard method of intramuscular injection survived the challenge.
Ebola causes devastating outbreaks with fatality rates of 25 to 90 percent in Africa and Asia. Although progress has been made in understanding the virus’ biology, no licensed vaccines or treatments currently exist.
“There is a desperate need for a vaccine that not only prevents the continued transmission from person to person, but also aids in controlling future incidences,” says Kristina Jonsson-Schmunk, a graduate student working with Maria Coyle, professor of pharmaceutics at University of Texas at Austin.
Long-lasting protection
“The main advantage of our vaccine platform over the others in clinical testing is the long-lasting protection after a single inhaled dose,” Croyle says. “This is important since the longevity of other vaccines for Ebola that are currently being evaluated is not fully evaluated.
“Moreover, this immunization method is more attractive than an injectable vaccine given the costs associated with syringe distribution and needle safety and disposal.”
The next stage of research is a phase I clinical trial that tests the effectiveness of the vaccine in human subjects. Croyle and colleagues will also further explore preliminary data they have collected for administration of the vaccine as a thin film under the tongue in non-human primates.
Croyle and colleagues will present their work November 5 at the 2014 American Association of Pharmaceutical Scientists Annual Meeting and Exposition. The National Institutes of Health provided funding.
Source: University of Texas at Austin
